Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents

Gain insights on the evolving role of BTK inhibitors for patients with CLL with an on-demand webcast downloadable slidesets and a podcast on frequently asked questions in CLL.

Share

Program Content

Activities

BTKi in CLL
Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 05, 2022

Expires: October 04, 2023

View Activity
EP: BTKi for CLL
ExpressPoints:
Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 10, 2022

Expires: October 09, 2023

View Activity

Activities

BTKi in CLL
Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2022

Expires: October 27, 2023

View Activity

Activities

BTKi Role in CLL
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: November 09, 2022

Expires: November 08, 2023

View Activity

Faculty

cover img faculity

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

ProCE Banner

Supporters

This CE activity is supported through an educational grant from

AstraZeneca

BeiGene

Lilly